Viracept is a drug owned by Agouron Pharmaceuticals Llc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 07, 2014. Details of Viracept's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6162812 (Pediatric) | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use |
Apr, 2014
(10 years ago) |
Expired
|
|
US5952343 (Pediatric) | HIV protease inhibitors |
Apr, 2014
(10 years ago) |
Expired
|
|
US5484926 (Pediatric) | HIV protease inhibitors |
Apr, 2014
(10 years ago) |
Expired
|
| US5952343 | HIV protease inhibitors |
Oct, 2013
(11 years ago) |
Expired
|
| US6162812 | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use |
Oct, 2013
(11 years ago) |
Expired
|
| US5484926 | HIV protease inhibitors |
Oct, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Viracept is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Viracept's family patents as well as insights into ongoing legal events on those patents.
Viracept's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Viracept's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 07, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Viracept Generics:
There are no approved generic versions for Viracept as of now.
Alternative Brands for Viracept
Viracept which is used for managing HIV infection., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie |
| |||||||||||||||||
| Bristol Myers Squibb |
| |||||||||||||||||
| Gilead |
| |||||||||||||||||
| Gilead Sciences |
| |||||||||||||||||
| Gilead Sciences Inc |
| |||||||||||||||||
| Glaxosmithkline |
| |||||||||||||||||
| Msd Sub Merck |
| |||||||||||||||||
| Roche |
| |||||||||||||||||
| Viiv Hlthcare |
| |||||||||||||||||
About Viracept
Viracept is a drug owned by Agouron Pharmaceuticals Llc. It is used for managing HIV infection. Viracept uses Nelfinavir Mesylate as an active ingredient. Viracept was launched by Agouron Pharms in 1997.
Approval Date:
Viracept was approved by FDA for market use on 14 March, 1997.
Active Ingredient:
Viracept uses Nelfinavir Mesylate as the active ingredient. Check out other Drugs and Companies using Nelfinavir Mesylate ingredient
Treatment:
Viracept is used for managing HIV infection.
Dosage:
Viracept is available in the following dosage forms - powder form for oral use, tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 250MG BASE | TABLET | Prescription | ORAL |
| EQ 625MG BASE | TABLET | Prescription | ORAL |
| EQ 50MG BASE/SCOOPFUL | POWDER | Discontinued | ORAL |